Top

Published in:

01-04-2018

Management of nonfunctioning pituitary tumors: radiotherapy

Authors: Giuseppe Minniti, John Flickinger, Barbara Tolu, Sergio Paolini

Published in: Pituitary | Issue 2/2018

Abstract

External beam radiotherapy (RT) is an essential part of the management of intracranial tumors and has been used in treating pituitary adenomas for more than five decades. It has been demonstrated that conventional RT for postoperative residual or progressive nonfunctioning pituitary adenomas (NFAs) present an excellent long-term local tumor control, although its use has been limited because of the potential late toxicity related to radiation treatments. Recent advances in radiation techniques have led to more accurate treatments, rendering obsolete many commonly held views of the “old” radiotherapy. New techniques include intensity modulated radiotherapy, volumetric-modulated arc therapy, and stereotactic techniques, either stereotactic radiosurgery or fractionated stereotactic radiotherapy. New techniques allow the delivering of higher radiation doses to the target with rapid dose fall-off in the surrounding normal tissues, and potentially limiting the long term toxicity of radiation. In this review, we present a critical analysis of the most recent available literature on the use of radiation in patients with NFAs, focusing particularly on the efficacy and safety of radiation stereotactic techniques.

Dekkers OM, Pereira AM, Romijn JA (2008) Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 93(10):3717–3726CrossRefPubMed

Murad MH, Fernández-Balsells MM, Barwise A, Gallegos-Orozco JF, Paul A, Lane MA, Lampropulos JF, Natividad I, Perestelo-Pérez L, Ponce de León-Lovatón PG, Albuquerque FN, Carey J, Erwin PJ, Montori VM (2003) Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clin Endocrinol 73(6):777–791CrossRef

Mortini P, Losa M, Barzaghi R, Boari N, Giovanelli M (2005) Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 56(6):1222–1233CrossRefPubMed

Minniti G, Jaffrain-Rea ML, Osti M, Cantore G, Enrici RM (2007) Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques. Neurosurg Rev 30(3):167–175CrossRefPubMed

Boelaert K, Gittoes NJ (2001) Radiotherapy for non-functioning pituitary adenomas. Eur J Endocrinology 144(6):569–575CrossRef

Al-Mefty O, Kersh JE, Routh A, Smith RR (1990) The long-term side effects of radiation therapy for benign brain tumours in adults. J Neurosurgery 73(4):502–512CrossRef

McCord MW, Buatti JM, Fennell EM, Mendenhall WM, Marcus RB Jr, Rhoton AL, Grant MB, Friedman WA (1997) Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J Radiat Oncol Biol Phys 39(2):437–444CrossRefPubMed

Peace KA, Orme SM, Padayatty SJ, Godfrey HP, Belchetz PE (1998) Cognitive dysfunction in patients with pituitary tumour who have been treated with transfrontal or transsphenoidal surgery or medication. Clin Endocrinol 49(3):391–396CrossRef

Guinan EM, Lowy C, Stanhope N, Lewis PD, Kopelman MD (1998) Cognitive effects of pituitary tumours and their treatments: two case studies and an investigation of 90 patients. J Neurol Neurosurg Psychiatry 65(6):870–876CrossRefPubMedPubMedCentral

10.

Brada M, Burchell L, Ashley S, Traish D (1999) The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys 45(3):693–698CrossRefPubMed

11.

Flickinger JC, Nelson PB, Taylor FH, Robinson A (1989) Incidence of cerebral infarction after radiotherapy for pituitary adenoma. Cancer 63(12):2404–2408CrossRefPubMed

12.

van Varsseveld NC, van Bunderen CC, Ubachs DH, Franken AA, Koppeschaar HP, van der Lely AJ, Drent ML (2015) Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the Dutch National Registry of Growth Hormone Treatment in Adults. J Clin Endocrinol Metab 100(3):1104–1112CrossRefPubMed

13.

Minniti G, Traish D, Ashley S, Gonsalves A, Brada M (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90(2):800–804CrossRefPubMed

14.

Minniti G, Gilbert DC, Brada M (2009) Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord 10(2):135–144CrossRefPubMed

15.

Leber KA, Berglöff J, Pendl G (1998) Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg 88(1):43–50CrossRefPubMed

16.

Tishler RB, Loeffler JS, Lunsford LD, Duma C, Alexander E 3rd, Kooy HM, Flickinger JC (1993) Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 27(2):215–221CrossRefPubMed

17.

Stafford SL, Pollock BE, Leavitt JA, Foote RL, Brown PD, Link MJ, Gorman DA, Schomberg PJ (2003) A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 55(5):1177–1181CrossRefPubMed

18.

Leavitt JA, Stafford SL, Link MJ, Pollock BE (2013) Long-term evaluation of radiation-induced optic neuropathy after single-fraction stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 87(3):524–527CrossRefPubMed

19.

Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J (2010) Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 76(3 Suppl):S28–S35CrossRefPubMed

20.

Meeks SL, Buatti JM, Foote KD, Friedman WA, Bova FJ (2000) Calculation of cranial nerve complication probability for acoustic neuroma radiosurgery. Int J Radiat Oncol Biol Phys 47(3):597–602CrossRefPubMed

21.

Feigl GC, Bonelli CM, Berghold A, Mokry M (2002) Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 97(5Suppl):415–421PubMed

22.

Vladyka V, Liscák R, Novotný J Jr, Marek J, Jezková J (2003) Radiation tolerance of functioning pituitary tissue in gamma knife surgery for pituitary adenomas. Neurosurgery 52:309–316CrossRefPubMed

23.

Leenstra JL, Tanaka S, Kline RW, Brown PD, Link MJ, Nippoldt TB et al (2010) Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas. Neurosurgery 67:27–32CrossRefPubMed

24.

Marek J, Jezková J, Hána V, Krsek M, Bandúrová L, Pecen L, Vladyka V, Liscák R (2011) Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell gamma knife? Eur J Endocrinol 164:169–178CrossRefPubMed

25.

Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML (2011) Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 114:303–309CrossRefPubMed

26.

Sicignano G, Losa M, del Vecchio A, Cattaneo GM, Picozzi P, Bolognesi A, Mortini P, Calandrino R (2012) Dosimetric factors associated with pituitary function after Gamma Knife Surgery (GKS) of pituitary adenomas. Radiother Oncol 104:119–124CrossRefPubMed

27.

Kuo JS, Yu C, Petrovich Z, Apuzzo ML (2008) The CyberKnife stereotactic radiosurgery system: description, installation, and an initial evaluation of use and functionality. Neurosurgery 162(Suppl 2):785–789

28.

Lamba M, Breneman JC, Warnick RE (2009) Evaluation of image-guided positioning for frameless intracranial radiosurgery. Int J Radiat Oncol Biol Phys 74(3):913–919CrossRefPubMed

29.

Wurm RE, Erbel S, Schwenkert I, Gum F, Agaoglu D, Schild R, Schlenger L, Scheffler D, Brock M, Budach V (2008) Novalis frameless image-guided noninvasive radiosurgery: initial experience. Neurosurgery 62(5 Suppl):A11–A17CrossRefPubMed

30.

Ramakrishna N, Rosca F, Friesen S, Tezcanli E, Zygmanszki P, Hacker F (2010) A clinical comparison of patient setup and intra-fraction motion using frame based radiosurgery versus a frameless image-guided radiosurgery system for intracranial lesions. Radiother Oncol 95:109–115CrossRefPubMed

31.

Gevaert T, Verellen D, Tournel K, Linthout N, Bral S, Engels B, Collen C, Depuydt T, Duchateau M, Reynders T, Storme G, De Ridder M (2012) Setup accuracy of the Novalis ExacTrac 6DOF system for frameless radiosurgery. Int J Radiat Oncol Biol Phys 82:1627–1635CrossRefPubMed

32.

Kim H, Potrebko P, Rivera A, Liu H, Eldredge-Hindy HB, Gunn V, Werner-Wasik M, Andrews DW, Evans JJ, Farrell CJ, Judy K, Shi W (2015) Tumor volume threshold for achieving improved conformity in VMAT and gamma knife stereotactic radiosurgery for vestibular schwannoma. Radiother Oncol 115(2):229–234CrossRefPubMed

33.

Ronson BB, Schulte RW, Han KP, Loredo LN, Slater JM, Slater JD (2006) Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys 64(2):425–434CrossRefPubMed

34.

Petit JH, Biller BM, Coen JJ, Swearingen B, Ancukiewicz M, Bussiere M, Chapman P, Klibanski A, Loeffler JS (2007) Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract 13(7):726–734CrossRefPubMed

35.

Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, Ancukiewicz M, Bussiere M, Klibanski A, Loeffler JS (2008) Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 93(2):393–399CrossRefPubMed

36.

Grigsby PW, Simpson JR, Emami BN, Fineberg BB, Schwartz HG (1989) Prognostic factors and results of surgery and postoperative irradiation in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys 16(6):1411–1417CrossRefPubMed

37.

McCollough WM, Marcus RB Jr, Rhoton AL Jr, Ballinger WE, Million RR (1991) Long-term follow-up of radiotherapy for pituitary adenoma: the absence of late recurrence after greater than or equal to 4500 cGy. Int J Radiat Oncol Biol Phys 21(3):607–614CrossRefPubMed

38.

Brada M, Rajan B, Traish D, Ashley S, Holmes-Sellors PJ, Nussey S, Uttley D (1993) The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol 38(6):571–578CrossRef

39.

Tsang RW, Brierly JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ (1994) Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys 30(3):557–565CrossRefPubMed

40.

Zierhut D, Flentje M, Adolph J, Erdmann J, Raue F, Wannenmacher M (1995) External radiotherapy of pituitary adenomas. Int J Radiat Oncol Biol Phys 33(2):307–314CrossRefPubMed

41.

Rush S, Cooper PR (1997) Symptom resolution, tumor control, and side effects following postoperative radiotherapy for pituitary macroadenomas. Int J Radiat Oncol Biol Phys 37(5):1031–1034CrossRefPubMed

42.

Breen P, Flickinger JC, Kondziolka D, Martinez AJ (1998) Radiotherapy for nonfunctional pituitary adenoma: analysis of long-term tumour control. J Neurosurg 89(6):933–938CrossRefPubMed

43.

Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN, Stewart PM (1998) Radiotherapy for non-function pituitary tumours. Clin Endocrinol 48(3):331–337CrossRef

44.

Sasaki R, Murakami M, Okamoto Y, Kono K, Yoden E, Nakajima T, Nabeshima S, Kuroda Y (2000) The efficacy of conventional radiation therapy in the management of pituitary adenoma. Int J Radiat Oncol Biol Phys 47(5):1337–1345CrossRefPubMed

45.

Langsenlehner T, Stiegler C, Quehenberger F, Feigl GC, Jakse G, Mokry M, Langsenlehner U, Kapp KS, Mayer R (2007) Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome. Strahlenther Onkol 183(5):241–247CrossRefPubMed

46.

Rim CH, Yang DS, Park YJ, Yoon WS, Lee JA, Kim CY (2011) Radiotherapy for pituitary adenomas: long-term outcome and complications. Radiat Oncol J 29(3):156–163CrossRefPubMedPubMedCentral

47.

Sebastian P, Balakrishnan R, Yadav B, John S (2016) Outcome of radiotherapy for pituitary adenomas. Rep Pract Oncol Radiother 21(5):466–472CrossRefPubMedPubMedCentral

48.

Scheick S, Amdur RJ, Kirwan JM, Morris CG, Mendenhall WM, Roper S, Friedman W (2016) Long-term outcome after fractionated radiotherapy for pituitary adenoma: the curse of the secretory tumor. Am J Clin Oncol 39(1):49–54CrossRefPubMed

49.

Woollons AC, Hunn MK, Rajapakse YR, Toomath R, Hamilton DA, Conaglen JV, Balakrishnan V (2000) Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol 53(6):713–717CrossRef

50.

Park P, Chandler WF, Barkan AL, Orrego JJ, Cowan JA, Griffith KA, Tsien C (2004) The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55(1):100–106CrossRefPubMed

51.

Tsang RW, Laperriere NJ, Simpson WJ, Brierley J, Panzarella T, Smyth HS (1993) Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 72(7):2227–2233CrossRefPubMed

52.

Feigl GC, Bonelli CM, Berghold A, Mokry M (2002) Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 97(5 Suppl):415–421PubMed

53.

Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD (2002) Radiosurgery for residual or recurrent non-functioning pituitary adenoma. J Neurosurg 97(5 Suppl):408–414PubMed

54.

Wowra B, Stummer W (2002) Efficacy of gamma knife radiosurgery for non-functioning pituitary adenomas: a quantitative follow-up with magnetic resonance imaging-based volumetric analysis. J Neurosurg 97(5 Suppl):429–432PubMed

55.

Petrovitch Z, Yu C, Giannotta SL, Zee CS, Apuzzo ML (2003) Gamma knife radiosurgery for pituitary adenoma: early results. Neurosurgery 53(1):51–59CrossRef

56.

Losa M, Valle M, Mortini P, Franzin A, da Passano CF, Cenzato M, Bianchi S, Picozzi P, Giovanelli M (2004) Gamma knife surgery for treatment of residual nonfunctioning pituitary adenomas after surgical debulking. J Neurosurg 100(3):438–444CrossRefPubMed

57.

Muacevic A, Uhl E, Wowra B (2004) Gamma knife radiosurgery for nonfunctioning pituitary adenomas. Acta Neurochir Suppl 91:51–54PubMed

58.

Iwai Y, Yamanaka K, Yoshioka K (2005) Radiosurgery for nonfunctioning pituitary adenomas. Neurosurgery 56(4):699–705CrossRefPubMed

59.

Picozzi P, Losa M, Mortini P, Valle MA, Franzin A, Attuati L, da Passano CF, Giovanelli M (2005) Radiosurgery and the prevention of regrowth of incompletely removed nonfunctioning pituitary adenomas. J Neurosurg 102(Suppl):71–74CrossRef

60.

Mingione V, Yen CP, Vance ML, Steiner M, Sheehan J, Laws ER, Steiner L (2006) Gamma surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg 104(6):876–883CrossRefPubMed

61.

Voges J, Kocher M, Runge M, Poggenborg J, Lehrke R, Lenartz D, Maarouf M, Gouni-Berthold I, Krone W, Muller RP, Sturm V (2006) Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer 107:1355–1364CrossRefPubMed

62.

Liscák R, Vladyka V, Marek J, Simonová G, Vymazal J (2007) Gamma knife radiosurgery for endocrine-inactive pituitary adenomas. Acta Neurochir 149(10):999–1006CrossRefPubMed

63.

Pollock BE, Cochran J, Natt N, Brown PD, Erickson D, Link MJ, Garces YI, Foote RL, Stafford SL, Schomberg PJ (2008) Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 70(5):1325–1329CrossRefPubMed

64.

Kobayashi T (2009) Long-term results of stereotactic gamma knife radiosurgery for pituitary adenomas. Specific strategies for different types of adenoma. Prog Neurol Surg 22:77–95CrossRefPubMed

65.

Hayashi M, Chernov M, Tamura N, Nagai M, Yomo S, Ochiai T, Amano K, Izawa M, Hori T, Muragaki Y, Iseki H, Okada Y, Takakura K (2010) Gamma Knife robotic microradiosurgery of pituitary adenomas invading the cavernous sinus: treatment concept and results in 89 cases. J Neurooncol 98(2):185–194CrossRefPubMed

66.

Gopalan R, Schlesinger D, Vance ML, Laws E, Sheehan J (2011) Long-term outcomes after Gamma Knife radiosurgery for patients with a nonfunctioning pituitary adenoma. Neurosurgery 69(2):284–293CrossRefPubMed

67.

Iwata H, Sato K, Tatewaki K, Yokota N, Inoue M, Baba Y, Shibamoto Y (2011) Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro Oncol 13(8):916–922CrossRefPubMedPubMedCentral

68.

Park KJ, Kano H, Parry PV, Niranjan A, Flickinger JC, Lunsford LD, Kondziolka D (2011) Long-term outcomes after gamma knife stereotactic radiosurgery for nonfunctional pituitary adenomas. Neurosurgery 69(6):1188–1199CrossRefPubMed

69.

Starke RM, Williams BJ, Jane JA Jr, Sheehan JP (2012) Gamma Knife surgery for patients with nonfunctioning pituitary macroadenomas: predictors of tumor control, neurological deficits, and hypopituitarism. J Neurosurg 117(1):129–135CrossRefPubMed

70.

Runge MJ, Maarouf M, Hunsche S, Kocher M, Ruge MI, El Majdoub F, Treuer H, Mueller RP, Voges J, Sturm V (2012) LINAC-radiosurgery for nonsecreting pituitary adenomas. Long-term results. Strahlenther Onkol 188(4):319–325CrossRefPubMed

71.

Wilson PJ, De-Loyde KJ, Williams JR, Smee RI (2012) A single centre’s experience of stereotactic radiosurgery and radiotherapy for nonfunctioning pituitary adenomas with the linear accelerator (Linac). J Clin Neurosci 19(3):370–374CrossRefPubMed

72.

Sheehan JP, Starke RM, Mathieu D, Young B, Sneed PK, Chiang VL, Lee JY, Kano H, Park KJ, Niranjan A, Kondziolka D, Barnett GH, Rush S, Golfinos JG, Lunsford LD (2013) Gamma knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg 119(2):446–456CrossRefPubMed

73.

Lee CC, Kano H, Yang HC, Xu Z, Yen CP, Chung WY, Pan DH, Lunsford LD, Sheehan JP (2014) Initial Gamma Knife radiosurgery for nonfunctioning pituitary adenomas. J Neurosurg 120(3):647–654CrossRefPubMed

74.

Bir SC, Murray RD, Ambekar S, Bollam P, Nanda A (2015) Clinical and radiologic outcome of gamma knife radiosurgery on nonfunctioning pituitary adenomas. J Neurol Surg B Skull Base 76(5):351–357CrossRefPubMedPubMedCentral

75.

Adler JR Jr, Gibbs IC, Puataweepong P, Chang SD (2006) Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions. Neurosurgery 59(2):244–254CrossRefPubMed

76.

Puataweepong P, Dhanachai M, Hansasuta A, Dangprasert S, Swangsilpa T, Sitathanee C, Jiarpinitnun C, Vitoonpanich P, Yongvithisatid P (2016) The clinical outcome of hypofractionated stereotactic radiotherapy with cyberknife robotic radiosurgery for perioptic pituitary adenoma. Technol Cancer Res Treat 15(6):NP10-NP15CrossRefPubMed

77.

Liao HI, Wang CC, Wei KC, Chang CN, Hsu YH, Lee ST, Huang YC, Chen HC, Hsu PW (2014) Fractionated stereotactic radiosurgery using the Novalis system for the management of pituitary adenomas close to the optic apparatus. J Clin Neurosci 2(1):111–115CrossRef

78.

Milker-Zabel S, Debus J, Thilmann C, Schegel W, Wannenmacher M (2001) Fractionated stereotactically guided radiotherapy and radiosurgery in the treatment of functional and non-functional adenomas of the pituitary gland. Int J Radiat Oncol Biol Phys 50(5):1279–1286CrossRefPubMed

79.

Paek SH, Downes MB, Bednarz G, Keane WM, Werner-Wasik M, Curran WJ Jr, Andrews DW (2005) Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas. Int J Radiat Oncol Biol Phys 61(3):795–808CrossRefPubMed

80.

Colin P, Jovenin N, Delemer B, Caron J, Grulet H, Hecart AC, Lukas C, Bazin A, Bernard MH, Scherpereel B, Peruzzi P, Nakib I, Redon C, Rousseaux P (2005) Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat Oncol Biol Phys 62(2):333–341CrossRefPubMed

81.

Minniti G, Traish D, Ashley S, Gonsalves A, Brada M (2006) Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clin Endocrinol 64(5):542–548CrossRef

82.

Kong DS, Lee JI, Lim DH, Kim KW, Shin HJ, Nam DH, Park K, Kim JH (2007) The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer 110(4):854–860CrossRefPubMed

83.

Schalin-Jäntti C, Valanne L, Tenhunen M, Setälä K, Paetau A, Sane T, Kouri M (2010) Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study. Clin Endocrinol 73(1):72–77

84.

Wilson PJ, De-Loyde KJ, Williams JR, Smee RI (2012) A single centre’s experience of stereotactic radiosurgery and radiotherapy for non-functioning pituitary adenomas with the linear accelerator (Linac). J Clin Neurosci 19(3):370–374CrossRefPubMed

85.

Kopp C, Theodorou M, Poullos N, Astner ST, Geinitz H, Stalla GK, Meyer B, Molls M, Nieder C, Grosu AL (2013) Fractionated stereotactic radiotherapy in the treatment of pituitary adenomas. Strahlenther Onkol 189(11):932–937CrossRefPubMed

86.

Kim JO, Ma R, Akagami R, McKenzie M, Johnson M, Gete E, Nichol A (2013) Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC cancer agency. Int J Radiat Oncol Biol Phys 87(3):528–533CrossRefPubMed

87.

Barber SM, Teh BS, Baskin DS (2016) Fractionated stereotactic radiotherapy for pituitary adenomas: single-center experience in 75 consecutive patients. Neurosurgery 79(3):406–417CrossRefPubMed

88.

Minniti G, Scaringi C, Poggi M, Jaffrain Rea ML, Trillò G, Esposito V, Bozzao A, Enrici MM, Toscano V, Enrici RM (2015) Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. Eur J Endocrinol 172(4):433–441CrossRefPubMed

89.

Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134:521–535CrossRefPubMed

90.

De Caro DB, Solari M, Pagliuca D, Villa F, Guadagno A, Cavallo E, Colao LM, Pettinato A, Cappabianca G P (2017) Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev 40(1):105–114CrossRef

Title: Management of nonfunctioning pituitary tumors: radiotherapy
Authors: Giuseppe Minniti
John Flickinger
Barbara Tolu
Sergio Paolini
Publication date: 01-04-2018
Publisher: Springer US
Published in: Pituitary / Issue 2/2018
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-018-0868-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Silent corticotroph adenomas

Histopathological classification of non-functioning pituitary neuroendocrine tumors

Pathogenesis of non-functioning pituitary adenomas

Management of NFAs: medical treatment

Non-functioning pituitary adenomas, not all the same and certainly not boring!

Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials